Lincoln Capital Corp Buys Shares of 9,404 Pfizer Inc. (NYSE:PFE)

Lincoln Capital Corp bought a new stake in Pfizer Inc. (NYSE:PFE) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 9,404 shares of the biopharmaceutical company’s stock, valued at approximately $261,000.

Several other large investors also recently bought and sold shares of PFE. VisionPoint Advisory Group LLC boosted its stake in shares of Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 1,047 shares during the last quarter. GoalVest Advisory LLC boosted its stake in shares of Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 811 shares during the last quarter. Creekmur Asset Management LLC acquired a new stake in shares of Pfizer during the fourth quarter valued at $32,000. Tennessee Valley Asset Management Partners acquired a new stake in shares of Pfizer during the fourth quarter valued at $36,000. Finally, DiNuzzo Private Wealth Inc. acquired a new stake in shares of Pfizer during the fourth quarter valued at $37,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on PFE. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Morgan Stanley increased their target price on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. BMO Capital Markets reiterated an “outperform” rating and set a $36.00 target price (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Wednesday. Ten investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and an average target price of $35.86.

Pfizer Trading Up 0.4 %

Shares of Pfizer stock traded up $0.12 during trading hours on Friday, reaching $27.92. The stock had a trading volume of 5,644,958 shares, compared to its average volume of 40,686,793. The firm has a 50 day simple moving average of $27.81 and a two-hundred day simple moving average of $27.69. The firm has a market capitalization of $158.21 billion, a price-to-earnings ratio of -467.09, a P/E/G ratio of 1.08 and a beta of 0.70. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $37.80.

Pfizer (NYSE:PFE) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, beating the consensus estimate of $0.56 by $0.26. The business had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The company’s revenue was down 19.5% on a year-over-year basis. During the same period last year, the business posted $1.23 EPS. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.38 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be issued a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, July 26th. This represents a $1.68 annualized dividend and a dividend yield of 6.02%. Pfizer’s payout ratio is currently -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.